TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED Ratings Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Singapore S.E.
Equities
T14
CNE100000924
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.43 USD | -2.02% |
|
+4.29% | +17.39% |
Strengths
- The company returns high margins, thereby supporting business profitability.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +17.39% | 3.1B | C | ||
| +9.94% | 4.99B | B- | ||
| -32.21% | 3.61B | C+ | ||
| -25.09% | 2.64B | B- | ||
| -11.46% | 2.32B | - | D+ | |
| +36.65% | 1.85B | - | ||
| +37.15% | 1.43B | - | ||
| -16.01% | 1.39B | - | - | |
| +40.95% | 1.37B | - | ||
| -26.42% | 1.3B | C- |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
-
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 600329 Stock
- T14 Stock
- Ratings Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited
